FR2506615A1 - Vaccin contre les brucelloses humaines et son procede de fabrication - Google Patents
Vaccin contre les brucelloses humaines et son procede de fabrication Download PDFInfo
- Publication number
- FR2506615A1 FR2506615A1 FR8110789A FR8110789A FR2506615A1 FR 2506615 A1 FR2506615 A1 FR 2506615A1 FR 8110789 A FR8110789 A FR 8110789A FR 8110789 A FR8110789 A FR 8110789A FR 2506615 A1 FR2506615 A1 FR 2506615A1
- Authority
- FR
- France
- Prior art keywords
- vaccine
- phenol
- brucella abortus
- fraction
- insoluble fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 39
- 241000589567 Brucella abortus Species 0.000 title claims abstract description 19
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 229940056450 brucella abortus Drugs 0.000 title claims abstract description 14
- 206010006500 Brucellosis Diseases 0.000 title claims abstract description 13
- 239000000725 suspension Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000005406 washing Methods 0.000 claims abstract description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000015961 delipidation Effects 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 5
- 241001148106 Brucella melitensis Species 0.000 abstract description 4
- 241001148111 Brucella suis Species 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 241000700198 Cavia Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 241000589562 Brucella Species 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 3
- 229940038698 brucella melitensis Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 108010050327 trypticase-soy broth Proteins 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 241000164109 Brucella abortus 544 Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010024769 Local reaction Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- OVHQWOXKMOVDJP-UHFFFAOYSA-N melitin Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(OC=2C=C3C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)=C(C=4C=CC(O)=CC=4)O3)=O)=C(O)C=2)OC(C)C1O OVHQWOXKMOVDJP-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000000601 reactogenic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241001600407 Aphis <genus> Species 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000007198 Bovine Brucellosis Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010060708 Induration Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010054827 Peritoneal lesion Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001533 brucellosis vaccines Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012297 crystallization seed Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002733 dermonecrotic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 231100001251 short-term toxicity Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/098—Brucella
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8110789A FR2506615A1 (fr) | 1981-06-01 | 1981-06-01 | Vaccin contre les brucelloses humaines et son procede de fabrication |
| GR68259A GR76448B (enrdf_load_stackoverflow) | 1981-06-01 | 1982-05-25 | |
| PT74968A PT74968B (fr) | 1981-06-01 | 1982-05-28 | Procede pour la preparation d'une vaccin contre les brucelloses humaines |
| AU84329/82A AU555214B2 (en) | 1981-06-01 | 1982-05-31 | Brucella vaccine |
| IT21603/82A IT1157306B (it) | 1981-06-01 | 1982-05-31 | Vaccino contro le brucellosi umane e procedimento per la sua preparazione |
| ES512691A ES8306594A1 (es) | 1981-06-01 | 1982-05-31 | "procedimiento de preparacion de una vacuna contra la brucelosis". |
| IL65920A IL65920A (en) | 1981-06-01 | 1982-05-31 | Anti-brucellosis vaccine and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8110789A FR2506615A1 (fr) | 1981-06-01 | 1981-06-01 | Vaccin contre les brucelloses humaines et son procede de fabrication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2506615A1 true FR2506615A1 (fr) | 1982-12-03 |
| FR2506615B1 FR2506615B1 (enrdf_load_stackoverflow) | 1984-10-26 |
Family
ID=9259055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8110789A Granted FR2506615A1 (fr) | 1981-06-01 | 1981-06-01 | Vaccin contre les brucelloses humaines et son procede de fabrication |
Country Status (7)
| Country | Link |
|---|---|
| AU (1) | AU555214B2 (enrdf_load_stackoverflow) |
| ES (1) | ES8306594A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2506615A1 (enrdf_load_stackoverflow) |
| GR (1) | GR76448B (enrdf_load_stackoverflow) |
| IL (1) | IL65920A (enrdf_load_stackoverflow) |
| IT (1) | IT1157306B (enrdf_load_stackoverflow) |
| PT (1) | PT74968B (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990006760A1 (en) * | 1988-12-13 | 1990-06-28 | Alberto Indrio | Pharmaceutical compositions containing brucella or derivatives thereof |
| WO1991009624A1 (en) * | 1989-12-22 | 1991-07-11 | Alberto Indrio | Pharmaceutical compositions for the treatment of drug dependence |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2398597C1 (ru) * | 2008-12-22 | 2010-09-10 | Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Сибирского отделения Российской академии сельскохозяйственных наук | Способ получения протективного антигенного комплекса бруцелл |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1587322A (enrdf_load_stackoverflow) * | 1963-09-19 | 1970-03-20 | ||
| FR2035795A1 (en) * | 1969-03-31 | 1970-12-24 | Merieux Inst | Anti-brucellosis vaccine prepn |
| FR2100920A1 (enrdf_load_stackoverflow) * | 1970-07-16 | 1972-03-24 | Wellcome Found | |
| GB1285057A (en) * | 1969-05-28 | 1972-08-09 | Secr Defence | Improvements in brucellosis vaccines |
| FR2287238A1 (fr) * | 1974-10-11 | 1976-05-07 | Agronomique Inst Nat Rech | Vaccin antibrucellique |
-
1981
- 1981-06-01 FR FR8110789A patent/FR2506615A1/fr active Granted
-
1982
- 1982-05-25 GR GR68259A patent/GR76448B/el unknown
- 1982-05-28 PT PT74968A patent/PT74968B/pt unknown
- 1982-05-31 IT IT21603/82A patent/IT1157306B/it active
- 1982-05-31 AU AU84329/82A patent/AU555214B2/en not_active Ceased
- 1982-05-31 IL IL65920A patent/IL65920A/xx not_active IP Right Cessation
- 1982-05-31 ES ES512691A patent/ES8306594A1/es not_active Expired
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1587322A (enrdf_load_stackoverflow) * | 1963-09-19 | 1970-03-20 | ||
| FR2035795A1 (en) * | 1969-03-31 | 1970-12-24 | Merieux Inst | Anti-brucellosis vaccine prepn |
| GB1285057A (en) * | 1969-05-28 | 1972-08-09 | Secr Defence | Improvements in brucellosis vaccines |
| FR2100920A1 (enrdf_load_stackoverflow) * | 1970-07-16 | 1972-03-24 | Wellcome Found | |
| FR2287238A1 (fr) * | 1974-10-11 | 1976-05-07 | Agronomique Inst Nat Rech | Vaccin antibrucellique |
Non-Patent Citations (4)
| Title |
|---|
| CA1976 * |
| EXBK/65 * |
| EXBK/72 * |
| EXBK/79 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990006760A1 (en) * | 1988-12-13 | 1990-06-28 | Alberto Indrio | Pharmaceutical compositions containing brucella or derivatives thereof |
| WO1991009624A1 (en) * | 1989-12-22 | 1991-07-11 | Alberto Indrio | Pharmaceutical compositions for the treatment of drug dependence |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2506615B1 (enrdf_load_stackoverflow) | 1984-10-26 |
| AU555214B2 (en) | 1986-09-18 |
| GR76448B (enrdf_load_stackoverflow) | 1984-08-10 |
| PT74968A (fr) | 1982-06-01 |
| IT8221603A0 (it) | 1982-05-31 |
| ES512691A0 (es) | 1983-06-01 |
| AU8432982A (en) | 1982-12-09 |
| IL65920A0 (en) | 1982-08-31 |
| ES8306594A1 (es) | 1983-06-01 |
| PT74968B (fr) | 1984-08-02 |
| IL65920A (en) | 1985-09-29 |
| IT1157306B (it) | 1987-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0623167B1 (fr) | Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie | |
| HU230199B1 (hu) | A Lawsonia intracellularis tenyésztése, anti-Lawsonia intracellularis vakcinák és diagnosztikumok | |
| Vershilova | The use of live vaccine for vaccination of human beings against brucellosis in the USSR | |
| Keskin et al. | Edwardsiella ictaluri infection in rainbow trout (Oncorhynchus mykiss) | |
| CN108179135B (zh) | 大肠杆菌噬菌体Esc-COP-7及其致病性大肠杆菌增殖抑制用途 | |
| Bunch-Christensen et al. | The virulence of some strains of BCG for golden hamsters | |
| FR2506615A1 (fr) | Vaccin contre les brucelloses humaines et son procede de fabrication | |
| JP2001520205A (ja) | ネオスポラワクチン | |
| Pinheiro et al. | Haemorrhagic syndrome of Altamira | |
| Krogstad et al. | Clinical and microbiologic characteristics of cutaneous infection with Yersinia enterocolitica | |
| JP2008074797A (ja) | 魚類滑走細菌症ワクチン | |
| BE1005589A3 (fr) | Medicament pour le traitement de la dermatite. | |
| Janseghers et al. | Fatal monkeypox in a child in Kikwit, Zaire | |
| FR2538703A1 (fr) | Vaccin vivant pour la prevention de la salmonellose des oiseaux aquatiques et procede pour sa preparation | |
| EP0082072B1 (fr) | Procédé de production d'un vaccin biochimique contre les fièvres à salmonelles | |
| EP0051522B1 (fr) | Mutant de septicémie hémorragique virale, vaccin contenant ce mutant et procédé pour sa préparation | |
| Avendano-Herrera et al. | Pseudo-membranes on internal organs associated with Rhodococcus qingshengii infection in Atlantic salmon (Salmo salar) | |
| Hyslop | Transmission of the virus of foot and mouth disease between animals and man | |
| BE1000189A3 (fr) | Preparation pharmaceutique a usage veterinaire. | |
| Vera-Cabrera et al. | Experimental mycetoma by Nocardia brasiliensis in rats | |
| FR2571618A1 (fr) | Nouveau vaccin contre la tracheobronchite infectieuse canine et son procede de preparation | |
| CH431819A (fr) | Procédé de préparation d'un vaccin | |
| EP0304374B1 (fr) | Préparations médicamenteuses à base de collagène et de dérivés imidazolés | |
| FR2524315A1 (fr) | Nouvel antigene pour la recherche de l'hypersensibilite cutanee brucellique notamment chez l'homme, et son procede de preparation | |
| FR2607392A1 (fr) | Procede pour la preparation d'une souche mutante de bordetella bronchiseptica utile pour la preparation d'un vaccin vivant attenue pour la prophylaxie des infections a b. bronchiseptica et vaccin vivant attenue contre la rhinite atrophique ainsi prepare |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |